PolarityTE® Supports Development of Utah Biotech and Life Sciences Community

SALT LAKE CITY, Oct. 29, 2018 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a commercial stage biotechnology company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences, announced today its continued support of the Utah biotech and life sciences community through sponsorship and participation in the Utah Life Sciences Summit 2018, the premier event for Utah companies on the front lines of medical innovation, hosted by BioUtah on November 1, 2018 in Salt Lake City.

PolarityTE chose to establish its headquarters in Utah because of the incredible opportunity to join a thriving and rapidly growing life science ecosystem. In less than two years, the Company has grown from a few doctors and scientists who initially left academic medicine to build the company, to more than 120 employees – most of whom were pulled from the impressive talent in Utah. PolarityTE values the collaborative business environment in Utah and appreciates the opportunities to connect with entities including the University of Utah, and state and local governments. Recently, PolarityTE leaders participated in the Governor's Trade Mission to South Korea and Taiwan to explore opportunities for PolarityTE to expand into international markets. Also, earlier this month, PolarityTE hosted Salt Lake City Mayor Jackie Biskupski at the PolarityTE Central Campus to discuss opportunities to work together to further develop the Salt Lake City biotech community. Through efforts like these and as members of BioUtah, the Company will continue to support the Utah life science community and BioUtah's goals of attracting and retaining life sciences talent and expanding the industry's presence and Utah's position on the global map of biotech hubs.

During the summit, PolarityTE will interact with other industry leaders, entrepreneurs, investors, economic analysts, educators and policy makers from the state. The Company has also sponsored the morning session, which will include discussions of how industry can influence lives of patients earlier, more effectively and more affordably.

"The Utah Life Sciences Summit will give us the opportunity to connect with other leaders and companies in Utah in a meaningful way. As we continue to grow, it is important for us to contribute as impactful corporate citizens in the state. Utah has helped PolarityTE thrive, and we look forward to ongoing and productive involvement as members of the community here," said Denver M. Lough, MD, PhD, Chairman and Chief Executive Officer of PolarityTE.

About PolarityTE®
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.

Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law. Our actual results could differ materially due to risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov).

POLARITYTE, the POLARITYTE logo, and SKINTE are trademarks or registered trademarks of PolarityTE, Inc.

CONTACTS

Investors:
Rich Haerle
VP, Investor Relations
PolarityTE, Inc.
[email protected] 
(385) 831-5284

Hans Vitzthum
LifeSci Advisors, LLC
[email protected] 
(617) 535-7743

Media:
Jenna Mathis
PolarityTE, Inc.
[email protected] 
(610) 751-3985

SOURCE PolarityTE, Inc.

Related Links

https://www.polarityte.com/